Todd C. Davis

Todd C. Davis

Chief Executive OfficeratLigand Pharmaceuticals· In proxies 2022–2025

Pay in FY2025-11% from the year before · Ligand Pharmaceuticals stock +76.5% the same year

Todd C. Davis was paid $11.5M in FY2025 (Dec), down 11%. Ligand Pharmaceuticals stock rose 76.5% that year.

Pay$100 in the stock at the end of FY21 → $122
Pay is from the Summary Compensation Table of each Ligand Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Ligand PharmaceuticalsPublic company · 4 yr
    • Chief Executive Officer2022 – Present · 4 yrStock in role +99%
  2. Benuvia Holdings, LLCPublic company
    • Director? – PresentNo stock prices for these years
  3. Channel Therapeutics CorporationPublic company
    • Director? – PresentNo stock prices for these years
  4. Chromocell Therapeutics CorporationPublic company
    • Director? – PresentNo stock prices for these years
  5. Palvella Therapeutics Inc.Public company
    • Director? – PresentNo stock prices for these years
  6. Pelthos Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  7. ViroCell BiologicsPublic company
    • Director? – PresentNo stock prices for these years
  8. BioDelivery Sciences InternationalPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?